Skip to main content
Clinical Trials/NCT05560906
NCT05560906
Recruiting
Not Applicable

Study of Virus-specific Lymphocytic Cell Populations in Non-invasive Nasal Mucosa Samples of MIS-C Patients, and Intra-population Shifts in Inflammatory Tissues in the Acute Phase of MIS-C and in Health

Medical University of Warsaw1 site in 1 country20 target enrollmentDecember 6, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
MIS-C Associated With COVID-19
Sponsor
Medical University of Warsaw
Enrollment
20
Locations
1
Primary Endpoint
Change in leukocyte subpopulations in nasal mucosa and peripherial blood during MIS-C and convalescence.
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The aim of the study is to make an accurate assessment of immune cells obtained from nasal mucosa and peripherial blood of MIS-C patients during the disease and the period of health.

Detailed Description

The study will consist of two parts. Initially, it will be of a cross-cutting comparative nature, when a group of healthy patients (control group) and a group of patients diagnosed with MIS-C/PIMS syndrome are compared with each other, based on nasal curettage swabs and peripheral blood, before the inclusion of systemic anti-inflammatory treatment (study group). In addition, an observation of the research group will be carried out, during which swabs and peripheral blood will be taken at two more control points.

Registry
clinicaltrials.gov
Start Date
December 6, 2021
End Date
December 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Medical University of Warsaw
Responsible Party
Principal Investigator
Principal Investigator

Wojciech Feleszko

Associate Professor, MD., PhD

Medical University of Warsaw

Eligibility Criteria

Inclusion Criteria

  • MIS-C diagnosis based of WHO diagnostic criteria.

Exclusion Criteria

  • immunosuppressive treatment received up to 3 months before
  • intranasal drugs received up to 7 days before
  • COVID-19 vaccination
  • no consent

Outcomes

Primary Outcomes

Change in leukocyte subpopulations in nasal mucosa and peripherial blood during MIS-C and convalescence.

Time Frame: Three clinical timepoints: (i) baseline (preferably before immunomodulatory treatment), (ii) convalescence, after major symptoms resolution (1 week +/-2 days after treatment introduction), (iii) outpatient control visit (6 weeks after hospital discharge)

The cellular subpopulations will be characterized and clustered using prepared immunomarker array.

Study Sites (1)

Loading locations...

Similar Trials